paolo carioli

[paolo carioli @PCarioli]

$DTIL
The inducement awards consist of an aggregate total of 114,622 restricted stock units (“RSUs”), granted among three employees in connection with their commencement of employment

https://t.co/G3SDvgCJN8

[BioWorld @BioWorld]

EMA reverses its stance on @AcadiaPharma’s Rett syndrome therapy Daybu
#biopharma #RettSyndrome #regulatory #Europe
https://t.co/WhhAa65QmF

[paolo carioli @PCarioli]

@dheurofkshe $DTIL

Precision BioSciences Announces Inclusion in the Russell 2000® Index Expanding Market Visibility with Institutional Investors

https://t.co/p3IhpuXjAA

[paolo carioli @PCarioli]

$DTIL sudden spike!!!

[International Rett Syndrome Foundation @Rettsyndrome]

Today, @AcadiaPharma announced that the EMA’s CHMP adopted a positive opinion, recommending marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and children aged 5 and older.

More: https://t.co/f24FVWbOEP

[paolo carioli @PCarioli]

$NEU

DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP

https://t.co/scGgtZjABI

[paolo carioli @PCarioli]

$NEU

[Bio Stocks™ @BioStocks]

$MPLT IRIS Phase 2 trial did not meet its primary endpoint in social communication deficits associated with ASD

https://t.co/qXMnNUtmsD

[paolo carioli @PCarioli]

$DTIL

[DB @OzzieChambers]

$TGTX Our #1 patient in the Azer-cel / Cart T therapy trial in the spotlight and now just passing the 1-year mark. Summer 2026: Momentum Magazine by Kimberly Kishpaugh - Flipsnack Page 26. The Azer trial is silently moving along in the background breaking new ground. 👍

[melinda @melindacapecod]

Thanks @AcadiaPharma for a super fun Rett-venture at the local LA YMCA. Katelin had fun showing off her newly enhanced swimming and coloring skills!

#KatelinRocksDaybue
#Rettsyndrome

[paolo carioli @PCarioli]

$DTIL

New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts - - In the <1% of cccDNA remaining

https://t.co/GzQuMzRKor

[melinda @melindacapecod]

#katelinRocksDaybue
#Rettsyndrome
@AcadiaPharma
@BrimbleM

[dough @semodough]

$TGTX AZER momentum continues to build - 2H26 catalyst- not on most radars

[paolo carioli @PCarioli]

$DTIL

[R @Lucy3370]

$tgtx I’ve found 3 positive Azer-cel stories. This is a sleeper in multi-billion opp for tgtx & potentially a massive game changer for PPMS patients
https://t.co/IW9Bf09Ma6

[paolo carioli @PCarioli]

$DTIL

iECURE Reports Sustained Clinical Response in the First Patient Dosed with ECUR-506 & Reductions in the Annualized Rates of Hyperammonemic Events and Crises in the First Completed Cohort of ECUR-506 in Ongoing OTC-HOPE Trial

https://t.co/1MbdecD3yP

[paolo carioli @PCarioli]

$DTIL Increased position:

Institutional Shares (Long)16,929,009 - 65.61% (ex 13D/G) - change of 5.48MM shares 47.83% MRQ

https://t.co/RXSzj99Bsk

[paolo carioli @PCarioli]

$DTIL

Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting

https://t.co/YnKAv56PUK

[paolo carioli @PCarioli]

$DTIL

I remember that:

Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting

Presentation Time: May 14, 2026 at 8:45 a.m. ET

https://t.co/gZnBTuNsti

[paolo carioli @PCarioli]

$DTIL

https://t.co/FpHPrnFOSK

[paolo carioli @PCarioli]

$DTIL

Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026

https://t.co/9Mby5i3i9A